Bio-Light Israeli Life Science Investments

BioLight Life Sciences is a leading Israeli investment company dedicated to the discovery, development, and commercialization of innovative technologies in the field of ophthalmology. The company manages a diverse portfolio of subsidiaries and investments that address significant unmet needs in eye care, including glaucoma, dry eye syndrome, and retinal diseases. BioLight's strategy involves identifying promising early-stage biomedical projects and providing the necessary capital and management expertise to bring them to market. Its portfolio includes advanced surgical devices, diagnostic tests, and novel drug delivery platforms. The company is publicly traded on the Tel Aviv Stock Exchange and has a track record of successful strategic exits, such as the sale of Belkin Vision to Alcon.